louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06670703: A Clinical Study of the Effects of Environmental Pollution on Obesity
Official title: A Clinical Study of the Effects of Environmental Pollution on Obesity
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Obesity and Overweight
Keywords: air pollution
obesity
prevalence
overweight
environment
Lead sponsor: First Affiliated Hospital of Chongqing Medical University
Sponsor class: OTHER
Collaborators: name: Affiliated Hospital of Yunnan University
name: The Second People's Hospital of Qujing
First posted: 2024-11-01
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is a retrospective observational study, which is expected to include patients diagnosed with obesity ( body mass index (BMI) ≥ 28 kg/m2).

Brief summary: This study aims to assess the effects of environmental pollution (including environmental indicators such as PM2.5, PM5, PM10, SO2, NOX, O3, and greening index) on obese patients and to explore the possible mechanisms by which environmental pollution promotes obesity.

Detailed description: Firstly, the effects of environmental pollution on obese patients were investigated by analysing the baseline conditions and obesity levels (including BMI, waist circumference, hip circumference, etc.) and underlying diseases of obese patients in regions with different pollution levels. Secondly, the association between environmental pollution levels on blood test characteristics (including renal function, sex hormones, glucose tolerance test, trace elements, liver function and blood routine) of obese patients was investigated to find possible mechanisms.

Eligibility criteria: Inclusion Criteria:

* Age ≥18 years;
* obese patients with BMI ≥30;
* patients without surgical treatment prior to enrolment;
* willingness to participate in the study and sign an informed consent form;
* complete clinical data.

Exclusion Criteria:

* patients with systemic diseases such as severe cardiorespiratory insufficiency affecting the choice of treatment regimen;
* patients assessed by the investigator to be inappropriate for enrolment;
* patients with incomplete clinical data.

Primary outcomes:
measure: incidence of obesity
timeFrame: From 18 years old until the developing obesity, through study completion, an average of 5 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
state: Chongqing
city: Kunming
country: China
facility: Affiliated Hospital of Yunnan University
state: Yunnan
city: Kunming
country: China
facility: The Second People's Hospital of Qujing
state: Yunnan
Study officials:
References:
Clinical trial NCT02019303: Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer
Official title: Ultrasound Guided Core Needle Biopsy Versus Fine Needle Aspiration of Morphologically Abnormal Axillary Lymph Node in Patients With New Diagnosis or Suspected Diagnosis of Invasive Breast Carcinoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: University of Utah
Sponsor class: OTHER
Collaborators: name: Huntsman Cancer Institute
First posted: 2013-12-24
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To compare accuracy of ultrasound guided fine needle aspiration (FNA) to core needle biopsy (CNB) of ultrasound detected abnormal axillary lymph nodes in patients with newly diagnosed invasive breast cancer or suspected invasive breast cancer.

Hypothesis: FNA and CNB have equivalent diagnostic accuracies

In order to prove our hypothesis, we will perform FNA and CNB on the same lymph node in each consented patient. The two samples will be evaluated separately by different pathologists blinded to the material in the other sample.

The results of the biopsies will be compared to the gold standard (lymph node excision).


Eligibility criteria: Inclusion Criteria:

* Recent or suspected diagnosis of invasive breast cancer with abnormal ipsilateral axillary lymph node
* Able to provide informed consent

Exclusion Criteria:

* Lymph node not amenable to core biopsy
* Patient is unlikely to undergo lymph node excision (i.e. elderly patient with co-morbidities)

Primary outcomes:
measure: Accuracy of FNA and CNB
timeFrame: 2 years
Secondary outcomes:
measure: Pain associated with FNA and CNB
timeFrame: 2 years
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Huntsman Cancer Hospital
state: Utah
Study officials:
References:
Clinical trial NCT01287403: Response of Alkylresorcinols to Different Cereals
Official title: Response of Alkylresorcinols and Other Biomarkers to Different Cereals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Cereals
Alkylresorcinols
Betaine
Phenolics
Plasma and urine cereal phytochemicals
Lead sponsor: Société des Produits Nestlé (SPN)
Sponsor class: INDUSTRY
First posted: 2011-02-01
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Cereal grains contain a wide variety of different phytochemicals which may play different roles in physiology. Their response in plasma and urine after a meal is poorly defined for most cereals. This study will investigate the plasma response and urinary excretion of cereal compounds after eating 6 different types of cereal preparation, with a focus on alkylresorcinols.

Detailed description: This was a cross-over, randomized, double blind study with 6 arms (flours of different composition). Thirteen subjects completed the trial, where 100 g of each flour, mixed with 300 mL milk, was fed to all subjects.

Eligibility criteria: Inclusion Criteria:

* Healthy
* Normal-overweight (BMI 19-28 kg/m2)
* Non-smokers

Exclusion Criteria:

* Regular consumers of wholegrain cereals
* Allergy to cereal or milk products

Primary outcomes:
measure: Plasma Alkylresorcinol Compounds
timeFrame: From 0 to 48 h post dose.
Secondary outcomes:
measure: Plasma and Urinary Betaine
timeFrame: From 0 to 48 hours post dose
measure: Phenolic Acids
timeFrame: 0-48 h post dose
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: NESTEC / Clinical Development Unit / Metabolic Unit
state: Vaud
Study officials:
affiliation: Société des Produits Nestlé (SPN)
name: Alastair B Ross, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01225003: Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas
Official title: Diffusion Kurtosis Imaging en MR Spectroscopy in Grading and the Characterization of Tumour Infiltration in Gliomas
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gliomas
Keywords: gliomas
magnetic resonance
diffusion kurtosis imaging
MR spectroscopy
grading
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2010-10-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients diagnosed with a gliomatuous brain tumor, prior to treatment

Brief summary: In this study, we evaluate the role of diffusion kurtosis imaging (DKI) and MR spectroscopy (MRS), two advanced imaging techniques in magnetic resonance (MR) in grading and detection of microscopic infiltrating tumour in gliomas. These parameters are of utmost importance in optimal choice and planning of treatment.

Patients treated with gliomatous brain tumours are included voluntarily. They undergo one imaging session on a 3T MR scanner prior to treatment.

DKI data are quantitively analyzed in order to estimate specific parameters in normal appearing white matter, grey matter, tumor and peritumoral edema. MRS data are analyzed quantitatively and qualitatively with peak integration, ratio calculation and classification algorithms. Histological confirmation is obtained at subsequent surgery.

Information from this study can be of significant importance in avoiding brain biopsies. Furthermore, information on microscopic tumour spread can be used during neurosurgery or in radiotherapy planning. An important advantage of these advanced MR techniques is the non-invasivity and the lack of ionizing radiation, two important issues in this relatively young patient population.


Eligibility criteria: Inclusion Criteria:

* diagnosis of gliomatous brain tumour

Exclusion Criteria:

* younger than 18 years of age
* prior treatment
* history of neurological or neurosurgical treatment

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: University Hospitals of Leuven
state: Vlaams-Brabant
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Stefan Sunaert, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Catholic University Leuven
name: Uwe Himmelreich, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00387803: Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation
Official title: VENTAK CHF/CONTAK CD Biventricular Pacing Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Heart Failure, Congestive
Ventricular Fibrillation
Tachycardia, Ventricular
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2006-10-13
Enrollment: 581
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.

Detailed description: Patients enrolled received a device with cardiac resynchronization therapy (CRT) and defibrillation. Patients were randomized to CRT on or off for up to six months and evaluated for mortality, hospitalization, and functional outcomes including exercise capacity, quality of life, symptomatic status, and echocardiographic analysis.

Eligibility criteria: Inclusion Criteria:

* Symptomatic heart failure
* Left ventricular ejection fraction \<= 35%
* QRS width \>= 120 ms
* Indicated for an implantable cardioverter defibrillator

Exclusion Criteria:

* Indicated for a pacemaker
* Atrial tachyarrhythmias

Primary outcomes:
measure: Composite of all-cause mortality, heart failure hospitalization, and ventricular tachyarrhythmia
Secondary outcomes:
measure: Peak VO2
measure: NYHA Class
measure: Six minute walk distance
measure: Quality of life
measure: Echocardiographic measures
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: Multiple locations
state: Minnesota
Study officials:
affiliation: Scripps Memorial Hospital
name: Steven Higgins, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California San Francisco Medical Center
name: Leslie A Saxon, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Milton S. Hershey Medical Center
name: John Boehmer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California San Francisco Medical Center
name: Teresa De Marco, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA, Boehmer JP, Higginbotham MB, De Marco T, Foster E, Yong PG. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003 Oct 15;42(8):1454-9. doi: 10.1016/s0735-1097(03)01042-8.
Clinical trial NCT00979303: Using Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia
Official title: The Adjunct Use of Non-Fluoroscopic Imaging Devices to Decrease Radiation Exposure During Ablation of Supraventricular Tachycardia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Supraventricular Tachycardia
Keywords: Pediatric
Electrophysiology
Ablation
Radiation
Devices
SVT
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2009-09-18
Enrollment: 74
Sex: ALL
Minimum age (years): 8
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Intent to treat use of non fluoroscopic mapping system with traditional fluoroscopic mapping system during elective catheter ablation in children 8-17 with normal cardiac anatomy
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the additional use of non-fluoroscopic imaging modalities can decrease the use of radiation exposure during standard ablation procedures for supraventricular tachycardia (SVT) in children.

Detailed description: The standard of care for children undergoing SVT ablation is radiation (fluoroscopy) to see the heart. Non fluoroscopic imaging tools have been utilized for adult atrial fibrillation procedures. These tools utilize magnetic fields to visualize the heart without using radiation. The purpose of this study was to determine if these 3D mapping tools could reduce radiation exposure during SVT ablation procedures could be performed using these 3D tools.

Eligibility criteria: Inclusion Criteria:

* Age \>/=8
* Weight \>/=25kg
* Structurally normal heart (no major cardiac defects)
* History of SVT
* No prior history of cardiac surgery or ablation

Exclusion Criteria:

* Congenital Heart Disease
* Prior history of cardiac surgery or ablation

Primary outcomes:
measure: Total Fluoroscopy Time
timeFrame: During the Ablation procedure
Secondary outcomes:
measure: Total Radiation Exposure
timeFrame: During Ablation Procedure
Other outcomes:
Locations:
city: Boston
country: United States
facility: Children's Hospital Boston
state: Massachusetts
Study officials:
affiliation: Boston Children's Hospital
name: Christina Y. Miyake, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Miyake CY, Mah DY, Atallah J, Oikle HP, Melgar ML, Alexander ME, Berul CI, Cecchin F, Walsh EP, Triedman JK. Nonfluoroscopic imaging systems reduce radiation exposure in children undergoing ablation of supraventricular tachycardia. Heart Rhythm. 2011 Apr;8(4):519-25. doi: 10.1016/j.hrthm.2010.12.022. Epub 2010 Dec 15.
Clinical trial NCT02721303: Appetite Regulation in Older-Aged Obese Individuals
Official title: Appetite Regulation in Older-Aged Obese Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Aging
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2016-03-29
Enrollment: 37
Sex: ALL
Minimum age (years): 21
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study plans to learn more about how age and weight impact appetite and food intake. Specifically, this study is being done to see whether age and obesity impact appetite and the brain's response to food. In this study the investigators will be evaluating how participants brains respond to food images as well as your food-related behaviors and hormones. The investigators will be comparing older individuals aged 65 to 85 years who are normal weight compared to those who are obese. The Investigators will then compare older aged individuals to younger adults aged 21 to 45 years.

Detailed description: In a cross sectional design participants will be studied on one occasion after a 3-day diet run-in. On the study day they will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken and appetite measures performed. Participants will then undergo functional magnetic resonance imaging (fMRI). This will be followed by a breakfast meal. Blood and appetite measures will be performed every half hour for 3 hours. Repeat fMRI will be performed 30 minutes after the meal. After three hours participants will be offered a buffet style lunch and then will be done with the study visit.

Eligibility criteria: Inclusion Criteria:

* Older aged adults (O): 65-85
* Younger adults (Y): 21-45
* Obese (Ob): body mass index (BMI) 30-40
* Normal Weight (NW): BMI 18-25

Exclusion Criteria:

* Pregnancy;
* Advanced organ failure;
* Active cancer diagnosis;
* Uncontrolled hypertension or metabolic disorder;
* Cognitive impairment or psychiatric disease limiting ability to comply;
* Presently in an exercise or diet program;
* Recent weight loss of \>5 lbs in past 6 mo.;
* Bariatric surgery;
* Use of any weight loss drugs;
* Use of any medication known to significantly affect appetite (anti-depressants are allowable);
* Present tobacco use;
* Use/abuse of substances of abuse including any marijuana use by history;
* Any contraindication to MRI;
* Claustrophobia;
* Body weight \>300 lbs; and
* Inability to fit in MRI scanner.

Primary outcomes:
measure: neuronal response to food images
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Univeristy of Colorado
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Marc-Andre Cornier, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00266903: Eisenmenger's Syndrome in Adults With CHD
Official title: Treatment of Eisenmenger's Syndrome in Adults With Congenital Heart Disease With Pulmonary Arterial Vasodilators
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Congenital Disorders
Keywords: adult
congenital heart disease
Eisenmenger's Syndrome
Bosentan
Sitaxsetan
Sildenafil
Lead sponsor: Children's Healthcare of Atlanta
Sponsor class: OTHER
First posted: 2005-12-20
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Congenital heart disease (unoperated, palliated or repaired) Eisenmenger's syndrome Age 18 to 80

Brief summary: Review the outcome of treatment with endothelin receptor antagonists (bosentan or sitaxsetan) alone or in combination with Sildenafil (a PDE-5 inhibitor) in adult patients with pulmonary hypertension due to congenital heart disease.

Detailed description: The primary objective of this study is to examine medical records of patients with Eisenmenger's Syndrome in order to determine the effect of endothelin receptor antagonists, alone or in combination, with Sildenafil, on symptoms of pulmonary hypertension. This review will be conducted on Standard of Care procedures such as New York Heart Association (NYHA) classification, six-minute walk exercise capacity, pulmonary pressures and oxygens saturations. Pulmonary pressures determined by echo or cardiac catheterization will be analyzed where available. We hypothesize that patients with congenital heart defects who develop ES will have an improved six-minute walk distance, improved pulmonary arterial pressures and improved oxygenation after treatment with endothelin receptor antagonists and other pulmonary vasodilators.

Eligibility criteria: Inclusion Criteria:

* Congenital heart disease (unoperated, palliated or repaired) Eisenmenger's syndrome Age 18 to 80

Exclusion Criteria:

* Those who do not meet inclusion criteria

Primary outcomes:
measure: Review the outcome of treatment with endothelin receptor antagonists (bosentan or sitaxsetan) alone or in combination with Sildenafil (a PDE-5 inhibitor) in adult patients with pulmonary hypertension due to congenital heart disease
timeFrame: 12 years
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Children's Healthcare of Atlanta
state: Georgia
Study officials:
affiliation: Emory University SOM
name: Wendy M. Book, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00812903: Neck Pain in Danish Military Pilots and Flight Crew
Official title: Neck Pain in Danish Military Pilots and Flight Crew - Environmental Factors With Influence on Performance (PH.D.-Project)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neck Pain
Keywords: Neck
Pain
Exercise
Pilots
Crew
Lead sponsor: University of Southern Denmark
Sponsor class: OTHER
Collaborators: name: Odense University Hospital
name: Danish Defence
name: Royal Danish Air Force
First posted: 2008-12-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine the prevalence of neck and shoulder pain in Danish fighter pilots, helicopter pilots and helicopter flight crew and to evaluate the effect of a 24 weeks exercise intervention for fighter pilots.


Eligibility criteria: Inclusion Criteria:

* Military fighter and helicopter pilots and crew
* Active flying 2006 or later

Exclusion Criteria:

* Pilots and crew not active since 2005 or earlier
* Pilots and crew with other nationality than Danish

Primary outcomes:
measure: Neck pain
timeFrame: 1 year
measure: Compliance to training exercises
timeFrame: 1 year
Secondary outcomes:
measure: Muscle strength
timeFrame: 1 year
Other outcomes:
Locations:
city: Vojens
country: Denmark
facility: Fighterwing Skrydstrup
Study officials:
affiliation: University of Souther Denmark
name: Gisela Sjoegaard, Professor
role: STUDY_DIRECTOR
References:
citation: Jones JA, Hart SF, Baskin DS, Effenhauser R, Johnson SL, Novas MA, Jennings R, Davis J. Human and behavioral factors contributing to spine-based neurological cockpit injuries in pilots of high-performance aircraft: recommendations for management and prevention. Mil Med. 2000 Jan;165(1):6-12.